Tenax Therapeutics (TENX) announced that the European Patent Office, EPO, has notified Tenax of its Intention to Grant a patent that will provide intellectual property, IP, protection for TNX-103, and other formulations of levosimendan, as well as its active metabolites, for use in pulmonary hypertension resulting from heart failure with preserved ejection fraction, PH-HFpEF. Once granted, this patent will provide Tenax with protection in Europe through 2040, and may qualify for an additional European patent term beyond 2040.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TENX:
- Tenax Therapeutics Expands Licensing Agreement with Orion
- Promising Potential of Tenax Therapeutics’ TNX-103 Drives Buy Rating Amid Positive Phase 2 Results and Anticipated Phase 3 Trial
- Tenax Therapeutics initiated with an Overweight at Piper Sandler
- Tenax Therapeutics Reports Q2 2025 Financial Results
- Tenax Therapeutics reports Q2 EPS (27c), consensus (45c)